These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11792135)

  • 1. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project.
    Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J
    Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study.
    Hague W; Forder P; Simes J; Hunt D; Tonkin A;
    Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up.
    LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease)
    Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expected versus observed survival in 3 large population studies with HMG-CoA reductase inhibitors.
    Naslafkih A; Sestier F
    J Insur Med; 2000; 32(3):155-62. PubMed ID: 15912915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program].
    Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB
    Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of mortality from coronary heart disease with pravastatin.
    Tonkin AM; Ryan EW
    Biomed Pharmacother; 1999 Oct; 53(9):405-8. PubMed ID: 10554675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pravastatin therapy and the risk of stroke.
    White HD; Simes RJ; Anderson NE; Hankey GJ; Watson JD; Hunt D; Colquhoun DM; Glasziou P; MacMahon S; Kirby AC; West MJ; Tonkin AM
    N Engl J Med; 2000 Aug; 343(5):317-26. PubMed ID: 10922421
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. White blood cell count predicts reduction in coronary heart disease mortality with pravastatin.
    Stewart RA; White HD; Kirby AC; Heritier SR; Simes RJ; Nestel PJ; West MJ; Colquhoun DM; Tonkin AM;
    Circulation; 2005 Apr; 111(14):1756-62. PubMed ID: 15809366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating average cholesterol levels in patients with coronary heart disease.
    Lindbloom EJ
    J Fam Pract; 1999 Feb; 48(2):94-5. PubMed ID: 10037537
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term follow-up of the West of Scotland Coronary Prevention Study.
    Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM;
    N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in cardiovascular mortality between Australia and New Zealand according to socioeconomic status: findings from the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study.
    Stewart RA; North FM; Sharples KJ; Simes RJ; Tonkin AM; White HD;
    N Z Med J; 2008 Feb; 121(1269):11-23. PubMed ID: 18278078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The microsomal triglyceride transfer protein gene-493T variant lowers cholesterol but increases the risk of coronary heart disease.
    Ledmyr H; McMahon AD; Ehrenborg E; Nielsen LB; Neville M; Lithell H; MacFarlane PW; Packard CJ; Karpe F;
    Circulation; 2004 May; 109(19):2279-84. PubMed ID: 15136504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment and secondary prevention of ischemic coronary events in Croatia (TASPIC-CRO study).
    Reiner Z; Mihatov S; Milicić D; Bergovec M; Planinc D;
    Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):646-54. PubMed ID: 16874158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
    Afilalo J; Duque G; Steele R; Jukema JW; de Craen AJ; Eisenberg MJ
    J Am Coll Cardiol; 2008 Jan; 51(1):37-45. PubMed ID: 18174034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-reactive protein and prediction of coronary heart disease and global vascular events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER).
    Sattar N; Murray HM; McConnachie A; Blauw GJ; Bollen EL; Buckley BM; Cobbe SM; Ford I; Gaw A; Hyland M; Jukema JW; Kamper AM; Macfarlane PW; Murphy MB; Packard CJ; Perry IJ; Stott DJ; Sweeney BJ; Twomey C; Westendorp RG; Shepherd J;
    Circulation; 2007 Feb; 115(8):981-9. PubMed ID: 17283264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of pravastatin on the function of dendritic cells in patients with coronary heart disease.
    Li X; Liu C; Cui J; Dong M; Peng CH; Li QS; Cheng JL; Jiang SL; Tian Y
    Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):101-6. PubMed ID: 19143751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
    Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beneficial effects of aggressive low-density lipoprotein cholesterol lowering in women with stable coronary heart disease in the Treating to New Targets (TNT) study.
    Wenger NK; Lewis SJ; Welty FK; Herrington DM; Bittner V;
    Heart; 2008 Apr; 94(4):434-9. PubMed ID: 18070940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.